Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors

• Status: Unknown status
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Cat's claw (Uncaria tomentosa) is a native amazonic plant that exhibits anti-inflammatory and antitumor properties. Patients and methods: This prospective phase II study will assess the effects of a 100-mg dose of a dry extract of U. tomentosa three times per day on individuals with advanced solid tumors, with no further therapeutic options and with at least 2 months life expectancy. In addition, several biochemical and inflammatory parameters will be analyzed.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Faculdade de Medicina do ABC

Criteria

Inclusion Criteria:

• individuals with advanced solid tumors, with no further therapeutic options and with at least 2 moths life expectancy

• individuals 18 years of age and older

• creatinine levels up to twice the upper limit of normal (ULN)

• alanine (ALT) and aspartate (ASP) transaminase levels up to twice the ULN and direct bilirubin (DB) levels up to 1.5 times the ULN

• in cases with pre-existing liver disease, the ALT, ASP and DB levels could be up to 2.5 times the ULN

Exclusion Criteria:

• pregnant and breastfeeding women

• individuals using chemotherapy or other tumor-targeting antineoplastic treatments, except for antalgic radiotherapy

• severe kidney or liver failure

• known hypersensitiveness to the components of the medication used

• past history of emotional disorders that could interfere with the data collection.